GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Short Percentage of Float

AVCNF (Avicanna) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is Avicanna Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Avicanna's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Avicanna's Short Percentage of Float falls into.


;
;

Avicanna Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » Short Percentage of Float
Comparable Companies
XCNQ:LEEF TSXV:DB XCNQ:IAN TSXV:LSL NEOE:CBST TSX:LABS TSXV:ROMJ XCNQ:CXXI XCNQ:AYR.A XCNQ:VEXT ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
0NN:Germany AVCN:Canada
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Website
https://www.avicanna.com
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.